Novavax Strikes $1.2 Billion Licensing Deal with Sanofi for COVID-19 Vaccine

7 views
Novavax obtains a licencing contract for up to $1.2 billion with Sanofi for its COVID-19 vaccine, involving stake in Novavax.
Novavax obtains a licencing contract for up to $1.2 billion with Sanofi for its COVID-19 vaccine, involving stake in Novavax.

Novavax secures a licensing deal worth up to $1.2 billion with Sanofi for its COVID-19 vaccine, entailing a stake in Novavax valued at double its current market capitalization.

After the announcement, Novavax’s stock more than doubled, reaching $9.29 before market opening, as investor sentiment rallied in response to the deal and removing previous business uncertainty.

Financial Implications:

Sanofi acquires a 4.9% stake in Novavax for $70 million, alongside an upfront cash payment of $500 million and additional future payments contingent on milestones and royalties, bolstering Novavax’s balance sheet.

Hedge fund Shah Capital views the deal positively, considering it a step forward for shareholders and potentially validating their push for a board shake-up at Novavax.

Strategic Benefits for Sanofi:

Sanofi is licensed to co-sell Novavax’s COVID-19 vaccine in most countries, enhancing its flu vaccine franchise and potentially enabling the development of combination vaccines with COVID-19 shots.

Novavax revises its 2024 sales forecast, excluding contributions from the Sanofi deal, to $400 million to $600 million, down from the previous estimate of $800 million to $1 billion.

Financial Performance:

Despite narrowing its net loss to $148 million in the first quarter from $294 million a year ago, Novavax faces ongoing challenges in navigating the competitive landscape and efficiently delivering its vaccine to the market.

James Adam

James Adam, a noted business writer for CEO Times Magazine, specializes in insightful industry analysis and executive profiles. Known for his clear, concise style, James offers readers an expert perspective on global business trends and market dynamics.

Previous Story

Global Pact to Combat Future Pandemics Likely to Miss Initial Deadline

Next Story

Ford Announces CFO Transition and Vice Chair Appointment

Latest from Business